SenesTech reported Q2 2024 revenues of $459,000, a 50% increase from $305,000 in Q2 2023, primarily driven by the successful launch of new products. Evolve, launched in January 2024, contributed 58% of quarterly revenue at $266,000. Gross profit margin improved to 54.2% from 46.4% year-over-year due to favorable product mix.Operating expenses decreased 14% to $1.85 million, with selling, general and administrative expenses declining 21% to $1.38 million due to lower personnel costs and professional fees. Research and development expenses increased 23% to $467,000 as the company realigned field development personnel to R&D activities.The company ended the quarter with $2.0 million in cash and expects current funding to support operations for at least three months. Management indicated additional financing will be needed before achieving anticipated revenue and margin targets, as the company continues to focus on commercializing fertility control products while managing operating expenses.

SenesTech reported Q2 2024 revenues of $459,000, a 50% increase from $305,000 in Q2 2023, primarily driven by the successful launch of new products. Evolve, launched in January 2024, contributed 58% of quarterly revenue at $266,000. Gross profit margin improved to 54.2% from 46.4% year-over-year due to favorable product mix.Operating expenses decreased 14% to $1.85 million, with selling, general and administrative expenses declining 21% to $1.38 million due to lower personnel costs and professional fees. Research and development expenses increased 23% to $467,000 as the company realigned field development personnel to R&D activities.The company ended the quarter with $2.0 million in cash and expects current funding to support operations for at least three months. Management indicated additional financing will be needed before achieving anticipated revenue and margin targets, as the company continues to focus on commercializing fertility control products while managing operating expenses.